introduced a novel diagnostic tool, the Roche RetinaScan™ System. This cutting-edge system uses advanced imaging techniques ...

CT scan of the chest revealed ground glass changes while blood tests indicated elevated inflammatory markers and a negative vasculitis screen. This included negative ANCA and anti-GBM antibodies.

Frailty was a significant predictor of severe infections within 2 years of ANCA-associated vasculitis diagnosis (adjusted hazard ratio [aHR], 8.46; 95% CI, 3.95-18.14), showing a stronger ...

Symptoms like fever ... or other major organs and may require surgical removal. Rheumatoid vasculitis occurs when the small blood vessels become inflamed. Narrowed blood vessels can lead to ...

anti-TNF-α therapy does not seem to be effective for this diagnosis. Granulomatosis with polyangiitis is characterized by the presence of a small- and medium-vessel vasculitis, and the presence ...

CCE is often overlooked because it mimics symptoms of systemic vasculitis due to its clinical characteristics such as ulceration and gangrene of toes, livedo reticularis, renal insufficiency. Acute ...

Furthermore, the nomenclature may be useful because it was proposed that certain symptoms and findings could be used as surrogate parameters—that is, the presence of proteinuria, haematuria, and red ...

Cambridge: AstraZeneca has announced that Fasenra (benralizumab) has been approved in the European Union (EU) as an add-on treatment for adult patients with relapsing or refractory ...

AstraZeneca’s Fasenra (benralizumab) has been approved in the European Union as an add-on treatment for adults with eosinophilic granulomatosis ...

World leading multifaculty knowledge, experience and innovation addressing the scientific, clinical and therapeutic challenges posed by vasculitis ...

New indication supported by the MANDARA trial, which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroidsAstraZeneca’s Fasenra (benralizumab) ...